Rare disease drugs get boost from new NICE guidelines
NICE has raised the cost-effectiveness thresholds for ultra-rare disease drugs under its Highly Specialised Technology programme – a move welcomed by patient advocates and biotech leaders.
List view / Grid view
NICE has raised the cost-effectiveness thresholds for ultra-rare disease drugs under its Highly Specialised Technology programme – a move welcomed by patient advocates and biotech leaders.
Researchers have unlocked the genetic secrets of soil’s hidden bacteria, discovering hundreds of previously unknown genomes and two promising new antibiotics.
Circulating tumour cell (CTC)-derived organoids are changing cancer research, providing scientists with a powerful tool for studying drug resistance and informing the development of new personalised therapies.
A new research study has discovered that targeted antioxidants could restore T cell function – offering a potential boost for cancer immunotherapies like CAR-T.
Researchers at the University of Birmingham have developed a single-cell technique to track boron inside live tumour cells – making Boron Neutron Capture Therapy more effective in treating head and neck cancers.
The Eurofins Assurance network has secured ISO/IEC 17065:2012 accreditation from ANAB for its Good Manufacturing Practices (GMP) certification programme.
Researchers have developed the first high-throughput tool to rapidly profile RNA modifications – a breakthrough that could lead to more precise treatments for cancer and antibiotic-resistant infections.
A new study has revealed that the protein GPNMB alters immune cells to aid cancer spread – pointing to the GPNMB-Siglec-9 pathway as a potential target for future treatments.
Researchers have discovered that Alzheimer’s disease is driven by a deeper loss of gene regulation in brain cells – offering potential new targets for future therapies.
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
King’s College London and Medicines Discovery Catapult have secured £400,000 from The Brain Tumour Charity to fast-track a new drug delivery approach for glioblastoma, the most aggressive brain cancer. The project will support preclinical studies to move potential treatments closer to patients.
Penn engineers have built an AI model that creates new antibiotics – and early tests show some work as well as existing approved drugs.
Northwestern University researchers have created DNA-coated nanoparticles that deliver CRISPR into cells three times more effectively while reducing toxicity. The advance could overcome one of the biggest barriers to gene-editing therapies.
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
Researchers have tested a new cancer drug in pet cats with head and neck squamous cell carcinoma – a disease notoriously hard to treat. The trial showed the therapy controlled cancer in 35 percent of cats with minimal side effects – and it could help to treat humans too.